Integra LifeSciences Holdings Corporation (IART) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Integra LifeSciences Holdings Corporation (IART) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Integra LifeSciences Holdings Corporation (IART) Q3 2025 Earnings Call Transcript
Integra LifeSciences Holdings Corporation ( IART ) Q3 2025 Earnings Call October 30, 2025 8:30 AM EDT Company Participants Christopher Ward - Senior Director of Investor Relations Mojdeh Poul - President, CEO & Director Lea Knight - Executive VP & CFO Conference Call Participants Vikramjeet Chopra - Wells Fargo Securities, LLC, Research Division Ryan Zimmerman - BTIG, LLC, Research Division Ravi Misra - Truist Securities, Inc., Research Division Lilia-Celine Lozada - JPMorgan Chase & Co, Research Division Presentation Operator Good day, and welcome to the Integra LifeSciences Third Quarter 2025 Financial Results. [Operator Instructions] As a reminder, this call may be recorded.
Integra (IART) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Integra (IART) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Integra LifeSciences (IART) Q3 Earnings Beat Estimates
Integra LifeSciences (IART) came out with quarterly earnings of $0.54 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.41 per share a year ago.
Integra LifeSciences Still Recovering From Self-Inflicted Wounds
Integra LifeSciences remains deeply discounted due to ongoing operational setbacks, with the market adopting a cautious 'show me' stance until clear improvements emerge. Remediation and margin improvement plans are underway, but shipping holds and tariffs continue to pressure revenue and profitability, delaying a full recovery until at least 2026. Core businesses, including higher-value wound care products, have shown resilience, and long-term growth drivers remain intact, supporting potential upside for patient investors.
Integra LifeSciences Holdings Corporation (IART) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Integra LifeSciences Holdings Corporation (NASDAQ:IART ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 8:30 AM EDT Company Participants Mojdeh Poul - President, CEO & Director Lea Knight - Executive VP & CFO Conference Call Participants Patrick Wood - Morgan Stanley, Research Division Presentation Patrick Wood MD of Equity Research Good morning, everyone, and welcome to Day 3 of the Morgan Stanley Global Healthcare Conference. Thanks so much, everyone, for joining.
Integra LifeSciences Holdings Corporation (IART) Q2 2025 Earnings Call Transcript
Integra LifeSciences Holdings Corporation (NASDAQ:IART ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Executives Christopher Ward – Senior Director of Investor Relations Lea Daniels Knight – Executive VP & CFO Mojdeh Poul – President, CEO & Director Analysts Lilia-Celine Breton Lozada - JPMorgan Chase & Co, Research Division Ravi Misra - Truist Securities, Inc., Research Division Unknown Analyst Vikramjeet Singh Chopra - Wells Fargo Securities, LLC, Research Division Xuyang Li - Jefferies LLC, Research Division Operator Good day, and thank you for standing by. Welcome to the Integra LifeSciences Second Quarter 2025 Financial Results Call.
Compared to Estimates, Integra (IART) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Integra (IART) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Integra LifeSciences (IART) Beats Q2 Earnings and Revenue Estimates
Integra LifeSciences (IART) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.63 per share a year ago.
IART Stock May Rise on First Enrollment in AERA Pediatric Registry
Integra enrolls first pediatric patient in AERA registry to evaluate real-world use of its ETBD system and expand ENT market presence.
Integra (IART) Up 2.3% Since Last Earnings Report: Can It Continue?
Integra (IART) reported earnings 30 days ago. What's next for the stock?
Is the Options Market Predicting a Spike in Integra LifeSciences Stock?
Investors need to pay close attention to Integra LifeSciences stock based on the movements in the options market lately.
